Radiopharm Theranostics (ASX:RAD) has announced the appointment of Dr Rama Abu Shmeis as its senior vice president of chemistry, manufacturing, and controls (CMC).
Dr Shmeis joins Radiopharm as a highly accomplished executive with 23 years of experience in strategic, operational and scientific aspects of CMC development and manufacturing across all stages, from pre-clinical through all clinical stages to commercialisation, covering a wide variety of dose forms, products and technologies.
Most recently, Dr Shmeis held the role of vice president of CMC and Manufacturing Operations at each of B-cell disease-focused TG Therapeutics and immunotherapy developer Checkpoint Therapeutics, serving at these NASDAQ-listed companies for more than five years.
Before that, her experience includes tenures with Eagle Pharmaceuticals, Keryx Biopharmaceuticals, Purdue Pharma, Sanofi- Aventis, Boehringer-Ingelheim Pharmaceuticals and Novartis Pharmaceutical.
Radiopharm’s CEO and managing director Riccardo Canevari, said, “We’re obviously thrilled to add another excellent senior team member with top-shelf experience in the USA market.”
“Dr Shmeis is known for developing creative solutions to complex problems in the sector, in addition to a strong ability to anticipate risk and therefore establish appropriate strategies to manage this. With a big picture focus and high-level attention to detail, we’re looking forward to her contribution to our vision at Radiopharm.”